文献速递肿瘤 PET/CT

18F-FDG PET/CT用于新诊断男性乳腺癌的系统分期

18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men.
PubMed 文献 · J Nucl Med · 2018-09-20

本研究回顾性分析了39例新诊断男性乳腺癌患者,评估18F-FDG PET/CT的系统分期价值。结果显示,18F-FDG PET/CT在16%的初始IIB期患者和33%的初始III期患者中发现了未被怀疑的远处转移,使分期上调至IV期。作者认为18F-FDG PET/CT对男性乳腺癌患者具有系统分期价值,可考虑用于新诊断患者,尤其是IIB期和III期患者。

要点

  • 18F-FDG PET/CT在18%的男性乳腺癌患者中发现了未被怀疑的远处转移。
  • 初始IIB期患者中16%(3/19)被上调至IV期,初始III期患者中33%(4/12)被上调至IV期。
  • 作者认为18F-FDG PET/CT可考虑用于新诊断男性乳腺癌患者,尤其是IIB期和III期患者。

核心结论

  • 18F-FDG PET/CT在16%的初始IIB期男性乳腺癌患者和33%的初始III期患者中发现了先前未被怀疑的远处转移。
  • 这些上调率与先前发表的女性患者数据相当。
  • 18F-FDG PET/CT对男性乳腺癌患者的系统分期具有价值,作者认为可考虑用于新诊断患者,尤其是IIB期和III期患者。

研究设计与样本

  • 经机构审查委员会批准的回顾性研究,检索2004年至2017年期间在本机构接受18F-FDG PET/CT的I-III期男性乳腺癌患者。
  • 纳入在系统治疗或放射治疗前接受18F-FDG PET/CT的男性乳腺癌患者,共39例符合标准。
  • 初始分期由乳腺X线摄影、超声或手术确定,中位年龄62岁(范围31-90岁),95%为导管癌,97%为雌激素受体阳性。

主要发现

  • 在14年期间,本机构共10124例独特患者因乳腺癌接受18F-FDG PET/CT,其中106例为男性,39例在初始分期时成像并符合纳入标准。
  • 39例患者中7例(18%)经18F-FDG PET/CT发现先前未被怀疑的远处转移,分期上调至IV期。
  • 初始IIB期患者中3/19(16%)和初始III期患者中4/12(33%)被上调至IV期。
  • 18F-FDG PET/CT还在1例患者中检测到未被怀疑的同步淋巴瘤。

关键数值与推荐

  • 初始IIB期患者上调至IV期的比例为16%(3/19)。
  • 初始III期患者上调至IV期的比例为33%(4/12)。
  • 总体上调至IV期的比例为18%(7/39)。

临床怎么用

  • 作者认为18F-FDG PET/CT对男性乳腺癌患者的系统分期具有价值,可考虑用于新诊断患者,尤其是IIB期和III期患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-FDG PET/CT has demonstrated substantial value in systemic staging of newly diagnosed breast cancer in women. However, it is not known whether breast cancer in male patients benefits similarly. This study assesses 18F-FDG PET/CT systemic staging in patients with newly diagnosed male breast cancer and determines detection rates for unsuspected distant metastases stratified by pre-PET/CT stage. Methods: In this Institutional Review Board-approved retrospective study, our Health Care Information System was screened for stage I-III male patients with breast cancer who underwent 18F-FDG PET/CT before systemic or radiation therapy from 2004 to 2017. Initial stage was determined by mammography, ultrasound, or surgery. 18F-FDG PET/CT was evaluated to identify unsuspected extraaxillary regional nodal and distant metastases, and a post-PET/CT stage was determined. Rates of upstaging to stage IV were determined for each initial stage. Results: During the 14-y period, 10,124 unique patients underwent 18F-FDG PET/CT for breast cancer at our institution. Of these, 106 patients were men, and 39 of these patients were imaged at initial staging and met the inclusion criteria. Median age was 62 y (range, 31-90 y), most had ductal carcinoma (95%), and most were estrogen receptor-positive (97%). In 7 of 39 patients (18%), 18F-FDG PET/CT identified previously unsuspected distant metastases, which increased patient stage to IV. This included 3 of 19 (16%) initial stage IIB patients and 4 of 12 (33%) initial stage III patients. 18F-FDG PET/CT also detected an unsuspected synchronous lymphoma in 1 patient. Conclusion:18F-FDG PET/CT revealed previously unsuspected distant metastases in 16% of male patients with pre-PET/CT stage IIB breast cancer and 33% of those with stage III breast cancer. These rates are comparable to previously published upstaging rates in female patients. 18F-FDG PET/CT demonstrates value for systemic staging of male patients with breast cancer and should be considered for use in newly diagnosed patients, particularly those with stage IIB and III disease.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ulaner GA, Juarez J, Riedl CC, et al. 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men. J Nucl Med. 2018. PMID: 30237211. doi:10.2967/jnumed.118.217836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。